FDA’s Woodcock to Retire After Career Marked by Controversy
- Longtime official left ‘indelible mark’ at agency: Califf
- Furor over short-cut approvals overshadowed end of tenure
This article is for subscribers only.
US Food and Drug Administration Deputy Commissioner Janet Woodcock will retire next year after nearly four decades at the regulator that were marked by controversy over support for unproven medications for rare, serious conditions.
Woodcock confirmed the news in an email.